A novel use for drotrecogin alfa (activated): successful treatment of septic shock associated with coccidioidomycosis.
We present 2 cases of septic shock associated with coccidioidomycosis that were successfully treated with drotrecogin alfa (activated) in combination with antifungal agents. The favorable outcomes, in light of the high mortality usually associated with this condition, suggest that drotrecogin alfa (activated) may be a valuable adjunct for treating septic shock due to endemic mycoses.
Crum
Nancy F
NF
Division of Infectious Diseases, Naval Medical Center San Diego, CA 92134-1005, USA. nfcrum@nmcsd.med.navy.mil
Groff
Harold L
HL
Parrish
John S
JS
Ring
William
W
D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D003047:Coccidioidomycosis / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011486:Protein C / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012074:Remission Induction; D012772:Shock, Septic / Q000188:drug therapy* / Q000209:etiology*
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated